Literature DB >> 8859265

Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection.

J Messer1, D Eyer, L Donato, H Gallati, J Matis, U Simeoni.   

Abstract

OBJECTIVE: To evaluate plasma levels of interleukin-6 (IL-6) and soluble tumor necrosis factor receptors (sTNF-R) 55 and 75 in neonates as a contribution to the early diagnosis of infection. STUDY
DESIGN: We prospectively measured IL-6 and sTNF-R 55 and sTNF-R 75 plasma levels in 157 newborn infants admitted to our regional neonatal center in a 3-month period and in cord blood of 131 newborn infants delivered in our obstetrics unit. C-reactive protein was sequentially determined after admission. Newborn infants were classified into four groups: group 0, not infected; group 1, possibly infected; group 2a, infected (culture positive), and group 2b, probably infected (culture negative). We looked for the optimal cutoff point of these parameters, using the receiver operating characteristics (ROC) curve.
RESULTS: IL-6 levels were significantly higher in group 2 (n = 11; median level, 250 pg/ml; range, 0 to 81,000), group 2b (n = 25; median level, 750 pg/ml; range, 0 to 180,000), and group 1 (n = 35; median level, 160 pg/ml; range 0 to 10,000), in comparison with group 0 (n = 217; median level, 0 pg/ml; range, 0 to 3400). A cutoff value of 100 pg/ml or greater obtained by the ROC method gives a sensitivity of 83.3% and a specificity of 90.3%. For inborn infants (n = 220) sampled at birth, sensitivity is 100% and specificity 92.3%. This high sensitivity persists until the twelfth hour of life. The sTNF-R 55 levels are significantly higher in group 2a (median, 12.0 ng/ml; range, 3.2 to 24.4). In group 2b (median, 7.0 ng/ml; range, 3.0 to 25.2), and in group 1 (median, 7.0 ng/ml; range, 2.5 to 18.9) than in group 0 (median, 3.9 ng/ml; range, 1.5 to 15.0), and with a cutoff value of 6 ng/ml, sensitivity is 75% and specificity 69%. The sTNF-R 75 levels are significantly higher in group 2a (median, 17.0 ng/ml; range, 7.2 to 48.8). In group 2b (median, 11.2 ng/ ml; range, (2.0 to 31.3), and in group 1 (median, 10.6 ng/ml; range, 2.0 to 33.0); than in group 0 (median, 7.0 ng/ml; range, 1 to 23.0). With a cutoff value of 9 ng/ ml, sensitivity is 80% and specificity 67%. Sensitivity of C-reactive protein is low initially but improves with time. Combining IL-6 with C-reactive protein provides the possibility of identifying the majority of infected infants in the postnatal period.
CONCLUSION: A plasma IL-6 level of 100 pg/ml or greater, obtained before the twelfth hour of life, appears to be an ideal marker for detecting early-onset neonatal infection with a high degree of sensitivity and specificity. After the twelfth hour, the combined determination of IL-6 and C-reactive protein may be equally useful. The sTNF-R levels appear to be less useful in the early diagnosis of infection because of their smaller magnitude of variation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8859265     DOI: 10.1016/s0022-3476(96)70123-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  22 in total

1.  Pre-inflammatory mediators and lymphocyte subpopulations in preterm neonates with sepsis.

Authors:  Efthalia Hotoura; Vasileios Giapros; Ageliki Kostoula; Polixeni Spyrou; Styliani Andronikou
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 2.  Diagnostic markers of infection in neonates.

Authors:  P C Ng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-05       Impact factor: 5.747

3.  Evaluation of IL-6, CRP and hs-CRP as Early Markers of Neonatal Sepsis.

Authors:  Purushothaman Ganesan; Priyadarshini Shanmugam; Shameem Banu Abdul Sattar; Shenbaga Lalitha Shankar
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 4.  The preterm parturition syndrome.

Authors:  R Romero; J Espinoza; J P Kusanovic; F Gotsch; S Hassan; O Erez; T Chaiworapongsa; M Mazor
Journal:  BJOG       Date:  2006-12       Impact factor: 6.531

Review 5.  The role of inflammation and infection in preterm birth.

Authors:  Roberto Romero; Jimmy Espinoza; Luís F Gonçalves; Juan Pedro Kusanovic; Lara Friel; Sonia Hassan
Journal:  Semin Reprod Med       Date:  2007-01       Impact factor: 1.303

6.  Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study.

Authors:  Marianna Parlato; François Philippart; Alexandra Rouquette; Virginie Moucadel; Virginie Puchois; Sophie Blein; Jean-Pierre Bedos; Jean-Luc Diehl; Olfa Hamzaoui; Djillali Annane; Didier Journois; Myriam Ben Boutieb; Laurent Estève; Catherine Fitting; Jean-Marc Treluyer; Alexandre Pachot; Minou Adib-Conquy; Jean-Marc Cavaillon; Benoît Misset
Journal:  Intensive Care Med       Date:  2018-06-30       Impact factor: 17.440

Review 7.  Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE).

Authors:  Daniel J Raiten; Fayrouz A Sakr Ashour; A Catharine Ross; Simin N Meydani; Harry D Dawson; Charles B Stephensen; Bernard J Brabin; Parminder S Suchdev; Ben van Ommen
Journal:  J Nutr       Date:  2015-04-01       Impact factor: 4.798

8.  Interleukin-8 (IL-8) preferable to IL-6 as a marker for clinical infection.

Authors:  Joern-Hendrik Weitkamp; Jochen Reinsberg; Peter Bartmann
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

Review 9.  Diagnostics for neonatal sepsis: current approaches and future directions.

Authors:  Pui-Ying Iroh Tam; Catherine M Bendel
Journal:  Pediatr Res       Date:  2017-06-28       Impact factor: 3.756

10.  Clinical chorioamnionitis at term VI: acute chorioamnionitis and funisitis according to the presence or absence of microorganisms and inflammation in the amniotic cavity.

Authors:  Roberto Romero; Piya Chaemsaithong; Nikolina Docheva; Steven J Korzeniewski; Juan P Kusanovic; Bo Hyun Yoon; Jung-Sun Kim; Noppadol Chaiyasit; Ahmed I Ahmed; Faisal Qureshi; Suzanne M Jacques; Chong Jai Kim; Sonia S Hassan; Tinnakorn Chaiworapongsa; Lami Yeo; Yeon Mee Kim
Journal:  J Perinat Med       Date:  2016-01       Impact factor: 1.901

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.